IL6 and cancer: As expected, IL-6–neutralized antibodies markedly diminished the ADSCs-induced up-regulation of these genes in cancer cells, including SOX2 (4T1, 0.87 ± 0.12; CT26, 1.24 ± 0.41), NANOG (4T1, 0.85 ± 0.33; CT26, 2.35 ± 0.64), ALDH1A1 (4T1, 0.6 ± 0.34; CT26, 3.8 ± 0.88), and ABCG2 (4T1, 0.95 ± 0.08; CT26, 0.96 ± 0.24) (Figure 5B).